Spelling suggestions: "subject:"cutaneous accell lymphoma"" "subject:"cutaneous 60cell lymphoma""
1 |
MicroRNAs in Cutaneous T-cell Lymphoma PathogenesisKohnken, Rebecca January 2017 (has links)
No description available.
|
2 |
Predictors of Quality of Life in Patients with Cutaneous T cell LymphomaDeaver, Darcie Marie 01 January 2013 (has links)
Abstract
Cutaneous T cell lymphoma (CTCL) is a rare, incurable, chronic disease accounting for approximately 3% of non-Hodgkin's lymphoma diagnoses every year. Patients with CTCL have skin lesions that can vary in severity putting patients at risk for developing symptoms that may impair their quality of life (QOL). The disease burden can lead to increased depressive symptoms, fatigue distress, and anxiety that the disease may be worsening. Seventy-five participants agreed to take part in an exploratory, prospective study to evaluate depressive symptoms, anxiety, fatigue distress, and spirituality as predictors of QOL in CTCL patients. Demographic variables including stage of disease, ethnicity, age, gender, marital status, level of education, and time since diagnosis, were also included in the analyses to assess for relationships. Bivariate correlations, t-tests, and regression analyses were conducted to assess for relationships among the predictor variables and QOL. The analyses revealed that the proposed model explained 64% of the variance, and depressive symptoms (t= -2.4, p= 0.020) and stage of disease (t= -3.0, p= 0.004) significantly predicted the QOL of CTCL patients. Evaluating for predictors that influence the QOL helps us to better understand the needs of the patients afflicted with CTCL. The importance of studying the QOL of the CTCL patients lies in the fact that nurses can assist in helping patients alleviate some of the symptoms they experience, thereby improving their QOL. Further study is warranted in developing interventions to assist in the preservation of QOL.
|
3 |
MEDIATORS AND RECEPTORS OF CHRONIC ITCH IN PRIMATES AND HUMANSNattkemper, Leigh January 2015 (has links)
Chronic itch has a significant impact on quality of life for millions of patients worldwide, on a level comparable to that of chronic pain. Yet, although there are a host of effective drugs available for pain, there are no therapies that specifically target chronic itch. Current experimental approaches to investigate the pathogenesis of chronic pruritus and to test novel therapeutic agents are largely limited to rodent models. However, rodent models display significant dermatological, neurophysiological, and immunological differences from humans with chronic itch. The disadvantages of the current rodent paradigms call for the design of a valid primate model of chronic itch. For four years, we have monitored scratching behavior in a primate colony (n=35) of Cynomolgus macaques (Macaca fascicularis) suffering from idiopathic chronic itch. By comparing molecular and genetic analyses of the primates’ skin to their quantified scratching behavior, we attempted to characterize the underlying mechanisms of chronic itch in this model. Furthermore, the expression of itch-related proteins was examined in both the primate model and in humans with pruritic diseases. The first aim of the study was to characterize the underlying molecular and genetic basis of chronic itch in the primate model. We were able to distinguish specific peripheral targets related to pruritus by correlating the genetic and protein expression results to the primates’ scratching severity. In Aim 1a, RNA-sequencing was performed on skin biopsies from the primates to identify differentially expressed genes in pruritic, lichenified versus non-pruritic, non-lichenified skin. These results were then correlated to the quantified primate scratching behavior. This led to the identification of over 400 genes that were differentially expressed in the skin based on scratching intensity. Many of these differentially expressed transcripts were associated with sensory nerve fibers, keratinocytes, mast cells, or lymphocytes. Selected genes that were overexpressed and correlated to itch intensity were then targeted for immunohistochemical and proteomic analysis in Aim 1b. Immunohistochemical examination of the primate skin biopsies revealed that histamine levels were not elevated in primates that exhibited increased scratching behavior. However, mast cells containing tryptase were significantly increased in the skin of primates with severe scratching as compared to primates with mild scratching. The increased levels of gastrin-releasing peptide and substance P in lichenified skin were also found to be correlated to the primates’ scratching behavior. Of note, transient receptor potential channels V1, V3, and A1 were increased in the epidermis of primate skin, but the numbers of TRPV1+ and TRPA1+ nerve fibers were not significantly different between lichenified and non-lichenified skin. Transcriptome analysis of the opioid receptors and their ligands showed that primates with severe scratching behavior had a significant imbalance between the µ- and κ-opioid receptors and ligands. The µ-opioids had upregulated gene expression, while the κ-opioids were downregulated. In Aim 2, to further characterize this primate model of chronic itch, we compared immunohistochemical results from the primate studies to human findings. Lesional and non-lesional skin biopsies from patients with atopic dermatitis, psoriasis, and cutaneous T-cell lymphoma underwent immunohistochemical analysis in order to reveal the similarities and differences between the primate model and different types of chronic itch in humans. As in the primate model, substance P was found to be increased in the skin of lesional atopic and psoriasis skin. Additionally, similar to primate skin, human atopic and psoriatic skin had high levels of tryptase and its receptor in the epidermis. While IL-31 was only slightly elevated in primates, patients with cutaneous T-cell lymphoma or atopic dermatitis showed a significant correlation between itch severity and IL-31 levels. In conclusion, our primate model displayed expression patterns of many endogenous pruritogens and receptors that were similar to those of humans with atopic dermatitis or psoriasis. While the primate model did not completely mimic these specific pruritic diseases, the overlap of pruritic components suggests a commonality of signaling pathways across several different chronic itch states. The similarity of this primate model to human disease offers the combined advantages of experimental modeling and long-term behavioral follow-up. / Biomedical Sciences
|
4 |
Caractérisation fonctionnelle des récepteurs NK à la surface des lymphocytes T CD4+ tumoraux et normauxRemtoula, Natacha 01 December 2009 (has links)
Le syndrome de Sézary (SS) est un variant leucémique et érythrodermique de lymphomes T cutanés. Il est caractérisé par la présence d’une population clonale de LT CD4+, présentant un noyau cérébriforme atypique, dans la peau, les ganglions lymphatiques et le sang périphérique. Après un bilan clinique, le diagnostic de cette pathologie est confirmé par l’analyse immunohistochimique d'une biopsie cutanée. Néanmoins, la cytomorphologie des cellules de Sézary circulantes n’est pas uniquement associée au SS. Notre laboratoire a identifié CD158k comme marqueur membranaire spécifique des cellules de Sézary. Ce récepteur offre un intérêt dans le diagnostic du SS et dans le suivi de l’évolution de la pathologie. Ainsi, nos résultats montrent qu’un immuno-marquage CD3+ CD158k+, analysé en cytométrie en flux, est une technique spécifique et sensible de détection de la cellule de Sézary par rapport à la cytomorphologie. Alors que dans plus de 30% des cas le SS passe inaperçu durant l’examen cytomorphologique, une analyse en cytométrie en flux permet la mise en évidence de cellules tumorales résiduelles. La présence systématique de CD158k à la surface des cellules de Sézary nous a conduit à rechercher l’expression d’autres KIRs. Sur les lymphocytes tumoraux circulants d’un patient ainsi que sur la lignée cellulaire correspondante, l’expression des formes activatrices et inhibitrices des récepteurs CD158a/h et CD158b/j est détectée. A la différence des lymphocytes NK et T CD8+, le récepteur présentant une fonction inhibitrice (KIR-L) ne l’emporte pas sur celui ayant une fonction activatrice (KIR-S) dans la cellule de Sézary. En fait, les KIR-L, à l’exception de CD158k, sont trouvés non fonctionnels dans la cellule tumorale. Ainsi, l’engagement des formes activatrices CD158h ou CD158j permet une régulation positive de la voie de signalisation CD3-dépendante de JNK et de la prolifération tumorale. Une étude fonctionnelle de la population T CD4+ KIR+, équivalent normal de la cellule de Sézary, a aussi été réalisée. Nous avons mis en évidence une expression préférentielle de la forme activatrice ou inhibitrice des récepteurs KIR homologues, selon le donneur. D’autre part, les KIRs activateurs ou inhibiteurs, exprimés à la surface des LT CD4+, jouent un rôle de co-récepteur vis-à-vis du TCR. Ainsi, une régulation positive ou négative de la prolifération et de la voie de signalisation CD3-dépendante de ERK est observée en fonction du type de récepteur co-engagé. Il est bien établi que les KIR-S s’associent à la molécule adaptatrice KARAP/DAP12 pour la transduction d’un signal d’activation. Dans les cellules T CD4+ saines et tumorales, la protéine recrutée par ces récepteurs est encore non identifiée. Notre étude sur la population T CD4+ CD158j+ de sujets sains montre l’implication de la protéine HS1 dans la signalisation mise en place par le récepteur KIR activateur. La réalisation de ce travail a permis de mieux comprendre les mécanismes mis en place à partir des KIRs dans les cellules T CD4+. Ce travail ouvre de nouvelles perspectives concernant le rôle de ces récepteurs dans les mécanismes permettant l'expansion tumorale des cellules de Sézary / Sézary syndrome (SS) is a leukemic and erythrodermic variant of cutaneous T-cell lymphomas. It is characterized by the presence of a clonal CD4+ T lymphocyte population in the skin, lymphnodes and peripheral blood. After clinical assessment, diagnosis of this disease is confirmed by immunohistochemistry analysis of a skin biopsy. However, the cytomorphology of circulating Sézary cells is not just associated to SS. Our laboratory has identified CD158k as a phenotypic marker for Sézary cells. This receptor can be used in the diagnosis of the SS and in monitoring the evolution of the disease. Our results show that the CD3/CD158k immunostaining, analysed by flow cytométrie, is more specific and sensitive than cytomorphology to detect atypical circulating cells. While more than 30% of the SS is misdiagnosed by the cytomorphologic identification, flow cytometry analysis allows the detection of residual tumor cells. Given the systemic expression of CD158k on Sézary cells, we next investigated the expression of additional KIRs. On circulating malignant lymphocytes from one patient and the corresponding cell line, the expression of inhibitory and activating forms of CD158a/h and CD158b/j receptors was detected. In contrast to NK cells and CD8+ T lymphocytes, the inhibitory receptor signaling (KIR-L) does not outweigh the activating receptor signaling (KIR-S) in the Sézary cell. In fact, KIR-L, except CD158k, are found not functional in the tumor cell. Thus, CD158h or CD158j engagement results in an enhanced CD3-induced cell proliferation and JNK activation. A functional study of CD4+ KIR+ T lymphocyte population, the normal equivalent of Sézary cells, was then performed. We observed an exclusive expression of the activating or the inhibitory form of KIR receptors, depending on the donor. Activating or inhibitory KIRs, expressed on the CD4+ T cell surface, act as coreceptors. Thus, a positive or negative regulation of the CD3-induced cell proliferation and ERK activation is observed by triggering the KIR-S or -L respectively. It is well known that stimulatory KIR initiates intracellular signals through their association with the adaptor protein KARAP/DAP12. However, in normal and malignant CD4+ T cells the protein recruited by these receptors is still not identified. Our study on CD4+ CD158j+ T lymphocyte population from healthy individuals showed the involvement of HS1 protein as a potential adaptor molecule in the activating KIR signaling pathway. This work has provided insight into the mechanisms of KIRs signaling in CD4+ T cells and opens new perspectives on the role of these receptors in proliferation of Sézary cells
|
5 |
Tumor-spezifische T-Zellen und T-Zellepitope bei kutanen LymphomenSharav, Tumenjargal 04 March 2005 (has links)
Ziel dieser Arbeit war die Identifizierung von Tumor-assozierten T-Zellepitopen (TATE) in kutanen T-Zelllymphomen (CTCL) und die Charakterisierung der Tumour-spezifischen zytotoxischen Immunabwehr. Zwei Tumor-spezifische T-Zellklone wurden aus den Tumor-infiltrierenden Lymphozyten (TIL) eines CTCL-Patienten etabliert. Die potentiellen natürlichen T-Zellepitope und Mimotope (synthetische Epitope ohne natürliche Korrelate aber mit meist hohen T-Zellaktivitäten) für diese Klone wurden mit einer kombinatorischen Peptidbibliothek identifiziert. Die Qualität und Quantität der T-Zellaktivitäten waren bei den jeweiligen Peptiden unterschiedlich. Die funktionellen Aviditäten varierten dabei um 3 Größenordnungen. Bei den einzelnen Peptiden korrelierte die Zytolyse und Zytokinsekretion nicht immer. Mit einigen Mimotopen wurden CTCL-Patienten für therapeutische Zwecke vakziniert. Die Frequenzen der Mimotop-spezifischen T-Zellen erhöhten sich während der ersten Vakzinationszyklen und tumorizide Aktivitäten konnten nachgewiesen werden. Diese ersten klinischen Anwendungen der Mimotope zeigen die Möglichkeit solcher Mimotope die sonst unzureichende Immunabwehr zu modulieren. Die Identifizierung neuer TATE ermöglichte die weitere Untersuchung der Tumor-spezifischen T-Zellen in der Peripherie und im Tumor des Patienten. Diese Analysen zeigten, dass diese Zellen im peripheren Blut aktiv aber im Tumor inaktiv waren. Die TILs waren vom effektor-memory Phänotyp expremierten aber nur schwach oder z. T. keine der Moleküle mit Effektorfunktion. Das immunsuppressive Zytokin TGF-beta könnte eine wichtige Rolle bei dieser unzureichenden Immunabwehr bei CTCL spielen. / The major goals of this work was the identification of tumour-associated T cell epitopes (TATE) in cutaneous T cell lymphoma (CTCL) and the characterisation of the tumour-specific cytolytic immune response. Two tumour-specific cytolytic T cell clones were established from the tumour-infiltrating lymphocytes (TIL) of one CTCL-patient. The potential natural T cell epitopes and mimotopes (epitopes without natural correlates but with more T cell stimulating capacity) for these T cell clones were identified using a combinatorial peptide library. The quantity and quality of the T cell response was different. The functional avidity of the peptides differed more than 3 orders of magnitude. The cytolysis and cytokine release did not correlate for each peptide. Some of the mimotopes were injected into CTCL-patients for therapeutic purpose. The frequency of the mimotope-specific T cell increased during the first vaccination cycles and a tumouricidal capacity could be observed. This first clinical application of the mimotopes showed the capacity of the mimotopes for the modulation of weak anti-tumour immune response. The identification of the new TATE allowed further characterisation of the tumour-specific T cells in the periphery and in the tumour of the patient. High frequency of the tumour-specific T cells could be detected in the tumour but they failed to show effector functions in comparison to the tumour-specific T cells in the peripheral blood. The tumour-specific T cells had the effector memory phenotype but expressed none or less amount of the cytolytic effector molecules. The reason for the suboptimal anti-tumour response in CTCL could be the immunesuppressive cytokine TGF-beta.
|
6 |
Análise comparativa da expressão e atividade das metaloproteinases 2 e 9 e de seus inibidores teciduais nas lesões cutâneas das variantes poiquilodérmica e clássica da micose fungoide / A comparative analysis of the expression and activity of metalloproteinases 2 and 9 and their tissue inhibitors in cutaneous lesions of poikilodermatous and classic variants of mycosis fungoidesBerg, Roberta Vasconcelos 10 June 2016 (has links)
Introdução: Micose fungoide poiquilodérmica (MFp) é uma variante clínica de micose fungoide (MF). É mais indolente e caracterizada pela presença da poiquilodermia. As metaloproteinases (MMP) e seus inibidores específicos TIMP (Tissue Inhibitors of Metaloproteinases) estão envolvidos na oncogênese. Especificamente as MMP2 e MMP9 e seus inibidores, TIMP-2 e TIMP-1, respectivamente, foram relacionados ao prognóstico em tumores. Poucos trabalhos estudaram MMP e nenhum estudou a ação dos TIMP na MF. Objetivos: avaliar a relação entre MMP2 e MMP9 e seus inibidores TIMP2 e TIMP1 e a agressividade da MF e descrever a casuística de micose fungoide poiquilodérmica no ambulatório de linfomas cutâneos da Divisão de Clínica Dermatológica do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Métodos: análise retrospectiva de 54 casos de MFp, sendo 25 de MFp localizada 14 de MFp generalizada e 15 de MFp mista. Para análise das MMP e TIMP, os grupos de MFp foram comparados com 7 amostras de pele normal (PN), 10 casos de MF clássica inicial (MFi), 9 casos de MF tumoral não-transformada (MFT nt) e 10 de MF tumoral transformada (MFT t). Resultados: A proporção de mulheres: homens foi 2,44. MFp apresentou maior tempo entre os primeiros sintomas e o diagnóstico. MFpG apresentou maior prevalência de lesões do tipo pitiríase liquenoide crônica (PLC) (79%). Houve alta prevalência de MF hipocromiante (62%) no grupo MFp mista. A histologia da MFp apresentou características típicas de MF e, adicionalmente, atrofia, telangectasias e derrame pigmentar, específicos da forma poiquilodérmica. Na imuno-histoquímica predominou o fenótipo CD3+, CD4+, CD7-, CD8- em todos os grupos, e MFp apresentou significantemente menor predomínio do fenótipo CD8+ que o grupo MFi. O grupo MFpG apresentou baixa positividade para pesquisa de clonalidade T da pele (12,5%). A MMP2 esteve mais presente na epiderme em MFi e MFp relativamente a MFT. Na derme superficial, os grupos MFi e MFp marcaram mais MMP2 que a pele normal, mas sem diferença estatística entre eles. Não houve diferença estatística em MMP2 na derme profunda entre os grupos. À zimografia, houve maior atividade de MMP2 ativa no grupo MFTt. Não houve expressão de TIMP-2 pela epiderme da pele normal. Os grupos MFi e MFp marcaram TIMP-2 na epiderme de forma semelhante, porém menos que os grupos MFT. Na derme superficial, não houve diferença estatística entre os grupos MFi e MFp. TIMP-2 foi mais expresso na derme profunda dos dois grupos de MFT comparativamente a todos os outros grupos. Na epiderme e na derme superficial, MMP9 foi mais expressa no grupo MFi comparativamente a MFp. Na derme profunda, a expressão de MMP9 foi maior nos grupos MFT, seguido por MFi e, por último, MFp. A atividade de MMP9 foi maior no grupo MFT não transformada comparativamente aos outros grupos. TIMP-1, ne epiderme e na derme superficial e na derme profunda foi mais expresso no grupo MFi, comparativamente aos outros grupos. Discussão: MFpG apresentou mais lesões tipo PLC e a forma mista, lesões hipocrômicas. A histologia da MFp foi semelhante à descrita previamente na literatura, mas a baixa positividade de CD8 difere de relatos prévios. A MMP2 pareceu ser um marcador de atividade para MF, principalmente quando a sua presença por imunohistoquímica foi associada a dados de zimografia. A expressão de MMP9 nas amostras foi compatível com os dados prévios de literatura, tendo sido mais expressa nas formas mais agressivas de MF e, histologicamente, mais localizada nos locais de maior atividade do tumor. TIMP-1 foi expresso de forma análoga à MMP9, conforme descrito previamente na literatura. TIMP-2, por sua vez, seguiu o padrão de distribuição de MMP2. No entanto, não foi expresso pela pele normal e foi mais expresso pelos grupos de MFT, o que não ocorreu com a MMP2 na imuno-histoquímica. Conclusões: A expressão de MMP e TIMP correlacionou-se com o local de maior atividade linfocitária e com a agressividade da MF. A atividade da MMP2 e MMP9 foi maior nos grupos MFT comparativamente aos grupos mais indolentes. Separar os casos de MFp de acordo com suas apresentações localizadas, generalizada e mista foi relevante do ponto de vista clínico, laboratorial e evolutivo / Introduction: poikilodermatous mycosis fungoides (pMF) is a clinical variant of mycosis fungoides (MF). It is more indolent than classic MF and is characterized by the presence of poikiloderma. The matrix metalloproteinases (MMPs) and their specific inhibitors TIMP (Tissue Inhibitors of Metalloproteinases) are involved in oncogenesis. Specifically, MMP2 and MMP9 and their inhibitors, TIMP-2 and TIMP-1, respectively, have been related to prognosis in tumors. There are few studies on MMP and none on the role of TIMPs in MF. Objectives: To evaluate if there is a relationship between the presence and activity of MMP2 and MMP9 and their inhibitors TIMP2 and TIMP1, and the aggressiveness of MF. To describe a casuistic of poikilodermatous mycosis fungoides in an outpatient clinic in the Dermatological Division of Hospital das Clinicas of University of Sao Paulo Medical School. Methods: Retrospective analysis of 54 cases of pMF, this included 25 localized pMF (LpMF), 14 generalized pMF (GpMF) and 15 mixed pMF. For the analysis of MMPs and TIMPs, the pMF groups were compared with 7 normal skin samples (NS), 10 cases of initial classical MF (cMF), 9 cases of non-transformed tumor MF (nt MFT) and 10 transformed tumor MF (t MFT). Results: The proportion of women : men was 2.44. The pMFs groups showed a longer period of time from the first symptoms to the diagnosis than the cMF group. The GpMF group had a higher incidence of pityriasis lichenoides chronica-like lesions (PLC) (79%) than the other groups. There was a high incidence of hypopigmented MF (62%) in the mixed pMF group. Histology showed typical characteristics of MF and, additionally, atrophy, telangiectasia and pigmentary alterations compatible with pMF. At immunohistochemistry the cases were predominantly CD3+, CD4+, CD7-, CD8- phenotype in all groups, and the pMF groups had a significantly lower prevalence of CD8+ phenotype than the cMF group. The GPMF group showed low positivity for clonality of the T-cell receptor at the T skin (12.5%) compared to the other groups. The MMP2 was more present in the epidermis for the cMF and pMF groups compared to MFT. In the superficial dermis, the cMF, LpMF and GpMF groups showed more MMP2 than normal skin, however there was no statistical difference between the three groups. There was no statistical difference in the presence of MMP2 in the deep dermis between the groups. The zymography showed higher MMP2 activity in the MFT group. There was no TIMP-2 expression by the normal epidermis. The epidermis of cMF and pMFs groups marked TIMP-2 in a similar way, but at a lower intensity than the MFT groups. In the superficial dermis, there was no statistical difference between the cMF and pMFs groups. TIMP-2 was more expressed in the deep dermis of the two MFT groups compared to all of the other groups. In the epidermis and superficial dermis, the MMP9 was more expressed in cMF compared to pMF groups. In the deep dermis, MMP9 expression was higher in the MFT groups, followed by cMF and finally pMF. The MMP9 activity was higher in the nt MFT group compared to other groups. TIMP-1, in epidermis, superficial dermis and deep dermis was more expressed in the cMF group compared to other groups. Discussion: The study confirmed that the pMF is an indolent form of MF and the time period between the symptoms and the diagnosis in pMF was longer than in classical MF. There were clinical differences amongst the groups of pMF. The GpMF group had a higher prevalence of PLC-like lesions than the mixed form of pMF, which had more hypochromic lesions. Histology of pMF was similar to descriptions provided in other case studies. However, the low CD8 positivity differs from previous reports. The MMP2 appeared to be a marker of activity for MF in our work, especially when their presence by immunohistochemistry was associated with the enzyme activity. The expression of MMP9 in our samples was consistent with previous data from other case studies, being more expressed in the most aggressive forms of MF and histologically more localized in most active sites of the tumor. TIMP-1 was expressed in an analogous manner to MMP9, as previously described in the literature. TIMP-2, in turn, followed the distribution pattern of MMP2. However, it was not expressed by normal skin and was more expressed by the MFT group, which did not occur with the MMP2 in immunohistochemistry. Conclusions: The expression of MMP and TIMP was correlated with the location of higher lymphocyte activity and with the aggressiveness of MF. The activity of MMP2 and MMP9 was higher in the MFT groups than the more indolent groups. It was important to split the pMF cases according to their presentation (GpMF, LpMF and mix pMF) from a clinical, laboratory and prognostic point of view
|
7 |
Análise comparativa da expressão e atividade das metaloproteinases 2 e 9 e de seus inibidores teciduais nas lesões cutâneas das variantes poiquilodérmica e clássica da micose fungoide / A comparative analysis of the expression and activity of metalloproteinases 2 and 9 and their tissue inhibitors in cutaneous lesions of poikilodermatous and classic variants of mycosis fungoidesRoberta Vasconcelos Berg 10 June 2016 (has links)
Introdução: Micose fungoide poiquilodérmica (MFp) é uma variante clínica de micose fungoide (MF). É mais indolente e caracterizada pela presença da poiquilodermia. As metaloproteinases (MMP) e seus inibidores específicos TIMP (Tissue Inhibitors of Metaloproteinases) estão envolvidos na oncogênese. Especificamente as MMP2 e MMP9 e seus inibidores, TIMP-2 e TIMP-1, respectivamente, foram relacionados ao prognóstico em tumores. Poucos trabalhos estudaram MMP e nenhum estudou a ação dos TIMP na MF. Objetivos: avaliar a relação entre MMP2 e MMP9 e seus inibidores TIMP2 e TIMP1 e a agressividade da MF e descrever a casuística de micose fungoide poiquilodérmica no ambulatório de linfomas cutâneos da Divisão de Clínica Dermatológica do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo. Métodos: análise retrospectiva de 54 casos de MFp, sendo 25 de MFp localizada 14 de MFp generalizada e 15 de MFp mista. Para análise das MMP e TIMP, os grupos de MFp foram comparados com 7 amostras de pele normal (PN), 10 casos de MF clássica inicial (MFi), 9 casos de MF tumoral não-transformada (MFT nt) e 10 de MF tumoral transformada (MFT t). Resultados: A proporção de mulheres: homens foi 2,44. MFp apresentou maior tempo entre os primeiros sintomas e o diagnóstico. MFpG apresentou maior prevalência de lesões do tipo pitiríase liquenoide crônica (PLC) (79%). Houve alta prevalência de MF hipocromiante (62%) no grupo MFp mista. A histologia da MFp apresentou características típicas de MF e, adicionalmente, atrofia, telangectasias e derrame pigmentar, específicos da forma poiquilodérmica. Na imuno-histoquímica predominou o fenótipo CD3+, CD4+, CD7-, CD8- em todos os grupos, e MFp apresentou significantemente menor predomínio do fenótipo CD8+ que o grupo MFi. O grupo MFpG apresentou baixa positividade para pesquisa de clonalidade T da pele (12,5%). A MMP2 esteve mais presente na epiderme em MFi e MFp relativamente a MFT. Na derme superficial, os grupos MFi e MFp marcaram mais MMP2 que a pele normal, mas sem diferença estatística entre eles. Não houve diferença estatística em MMP2 na derme profunda entre os grupos. À zimografia, houve maior atividade de MMP2 ativa no grupo MFTt. Não houve expressão de TIMP-2 pela epiderme da pele normal. Os grupos MFi e MFp marcaram TIMP-2 na epiderme de forma semelhante, porém menos que os grupos MFT. Na derme superficial, não houve diferença estatística entre os grupos MFi e MFp. TIMP-2 foi mais expresso na derme profunda dos dois grupos de MFT comparativamente a todos os outros grupos. Na epiderme e na derme superficial, MMP9 foi mais expressa no grupo MFi comparativamente a MFp. Na derme profunda, a expressão de MMP9 foi maior nos grupos MFT, seguido por MFi e, por último, MFp. A atividade de MMP9 foi maior no grupo MFT não transformada comparativamente aos outros grupos. TIMP-1, ne epiderme e na derme superficial e na derme profunda foi mais expresso no grupo MFi, comparativamente aos outros grupos. Discussão: MFpG apresentou mais lesões tipo PLC e a forma mista, lesões hipocrômicas. A histologia da MFp foi semelhante à descrita previamente na literatura, mas a baixa positividade de CD8 difere de relatos prévios. A MMP2 pareceu ser um marcador de atividade para MF, principalmente quando a sua presença por imunohistoquímica foi associada a dados de zimografia. A expressão de MMP9 nas amostras foi compatível com os dados prévios de literatura, tendo sido mais expressa nas formas mais agressivas de MF e, histologicamente, mais localizada nos locais de maior atividade do tumor. TIMP-1 foi expresso de forma análoga à MMP9, conforme descrito previamente na literatura. TIMP-2, por sua vez, seguiu o padrão de distribuição de MMP2. No entanto, não foi expresso pela pele normal e foi mais expresso pelos grupos de MFT, o que não ocorreu com a MMP2 na imuno-histoquímica. Conclusões: A expressão de MMP e TIMP correlacionou-se com o local de maior atividade linfocitária e com a agressividade da MF. A atividade da MMP2 e MMP9 foi maior nos grupos MFT comparativamente aos grupos mais indolentes. Separar os casos de MFp de acordo com suas apresentações localizadas, generalizada e mista foi relevante do ponto de vista clínico, laboratorial e evolutivo / Introduction: poikilodermatous mycosis fungoides (pMF) is a clinical variant of mycosis fungoides (MF). It is more indolent than classic MF and is characterized by the presence of poikiloderma. The matrix metalloproteinases (MMPs) and their specific inhibitors TIMP (Tissue Inhibitors of Metalloproteinases) are involved in oncogenesis. Specifically, MMP2 and MMP9 and their inhibitors, TIMP-2 and TIMP-1, respectively, have been related to prognosis in tumors. There are few studies on MMP and none on the role of TIMPs in MF. Objectives: To evaluate if there is a relationship between the presence and activity of MMP2 and MMP9 and their inhibitors TIMP2 and TIMP1, and the aggressiveness of MF. To describe a casuistic of poikilodermatous mycosis fungoides in an outpatient clinic in the Dermatological Division of Hospital das Clinicas of University of Sao Paulo Medical School. Methods: Retrospective analysis of 54 cases of pMF, this included 25 localized pMF (LpMF), 14 generalized pMF (GpMF) and 15 mixed pMF. For the analysis of MMPs and TIMPs, the pMF groups were compared with 7 normal skin samples (NS), 10 cases of initial classical MF (cMF), 9 cases of non-transformed tumor MF (nt MFT) and 10 transformed tumor MF (t MFT). Results: The proportion of women : men was 2.44. The pMFs groups showed a longer period of time from the first symptoms to the diagnosis than the cMF group. The GpMF group had a higher incidence of pityriasis lichenoides chronica-like lesions (PLC) (79%) than the other groups. There was a high incidence of hypopigmented MF (62%) in the mixed pMF group. Histology showed typical characteristics of MF and, additionally, atrophy, telangiectasia and pigmentary alterations compatible with pMF. At immunohistochemistry the cases were predominantly CD3+, CD4+, CD7-, CD8- phenotype in all groups, and the pMF groups had a significantly lower prevalence of CD8+ phenotype than the cMF group. The GPMF group showed low positivity for clonality of the T-cell receptor at the T skin (12.5%) compared to the other groups. The MMP2 was more present in the epidermis for the cMF and pMF groups compared to MFT. In the superficial dermis, the cMF, LpMF and GpMF groups showed more MMP2 than normal skin, however there was no statistical difference between the three groups. There was no statistical difference in the presence of MMP2 in the deep dermis between the groups. The zymography showed higher MMP2 activity in the MFT group. There was no TIMP-2 expression by the normal epidermis. The epidermis of cMF and pMFs groups marked TIMP-2 in a similar way, but at a lower intensity than the MFT groups. In the superficial dermis, there was no statistical difference between the cMF and pMFs groups. TIMP-2 was more expressed in the deep dermis of the two MFT groups compared to all of the other groups. In the epidermis and superficial dermis, the MMP9 was more expressed in cMF compared to pMF groups. In the deep dermis, MMP9 expression was higher in the MFT groups, followed by cMF and finally pMF. The MMP9 activity was higher in the nt MFT group compared to other groups. TIMP-1, in epidermis, superficial dermis and deep dermis was more expressed in the cMF group compared to other groups. Discussion: The study confirmed that the pMF is an indolent form of MF and the time period between the symptoms and the diagnosis in pMF was longer than in classical MF. There were clinical differences amongst the groups of pMF. The GpMF group had a higher prevalence of PLC-like lesions than the mixed form of pMF, which had more hypochromic lesions. Histology of pMF was similar to descriptions provided in other case studies. However, the low CD8 positivity differs from previous reports. The MMP2 appeared to be a marker of activity for MF in our work, especially when their presence by immunohistochemistry was associated with the enzyme activity. The expression of MMP9 in our samples was consistent with previous data from other case studies, being more expressed in the most aggressive forms of MF and histologically more localized in most active sites of the tumor. TIMP-1 was expressed in an analogous manner to MMP9, as previously described in the literature. TIMP-2, in turn, followed the distribution pattern of MMP2. However, it was not expressed by normal skin and was more expressed by the MFT group, which did not occur with the MMP2 in immunohistochemistry. Conclusions: The expression of MMP and TIMP was correlated with the location of higher lymphocyte activity and with the aggressiveness of MF. The activity of MMP2 and MMP9 was higher in the MFT groups than the more indolent groups. It was important to split the pMF cases according to their presentation (GpMF, LpMF and mix pMF) from a clinical, laboratory and prognostic point of view
|
Page generated in 0.0515 seconds